Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Status: Enrolling
Updated:  12/31/1969
University of Washington Autism Center
mi
from
Seattle, WA
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Intervention Effects of Intensity and Delivery Style for Toddlers With Autism
Status: Enrolling
Updated: 12/31/1969
University of Washington Autism Center
mi
from
Seattle, WA
Click here to add this to my saved trials
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
Status: Enrolling
Updated:  12/31/1969
Jackson Memorial Hospital
mi
from
Miami, FL
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
Status: Enrolling
Updated: 12/31/1969
Jackson Memorial Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
Status: Enrolling
Updated:  12/31/1969
University of Miami Hospital
mi
from
Miami, FL
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke
Status: Enrolling
Updated: 12/31/1969
University of Miami Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury
The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury
Status: Enrolling
Updated:  12/31/1969
University of Florida Health Science Center
mi
from
Gainesville, FL
The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury
The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury
Status: Enrolling
Updated: 12/31/1969
University of Florida Health Science Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated:  12/31/1969
Massachusetts Eye and Ear
mi
from
Boston, MA
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated: 12/31/1969
Massachusetts Eye and Ear
mi
from
Boston, MA
Click here to add this to my saved trials
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
UCLA David Geffen School of Medicine
mi
from
Los Angeles, CA
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
UCLA David Geffen School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Palo Alto, CA
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Rutgers Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Rutgers Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina Medical Center
mi
from
Charleston, SC
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina Medical Center
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Utah Health Care
mi
from
Salt Lake City, UT
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Utah Health Care
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Liverpool Hospital
mi
from
Liverpool,
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Liverpool Hospital
mi
from
Liverpool,
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
University of California, Davis Medical Center
mi
from
Sacramento, CA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Kennedy Krieger Institute
mi
from
Baltimore, MD
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Kennedy Krieger Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
St. Louis Children's Hospital
mi
from
Saint Louis, MO
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
St. Louis Children's Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy
A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With
Status: Enrolling
Updated:  12/31/1969
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy
A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With
Status: Enrolling
Updated: 12/31/1969
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Atomoxetine in Veterans With Comorbid ADHD/PTSD
Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study
Status: Enrolling
Updated:  12/31/1969
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Atomoxetine in Veterans With Comorbid ADHD/PTSD
Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study
Status: Enrolling
Updated: 12/31/1969
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Click here to add this to my saved trials
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Status: Enrolling
Updated:  12/31/1969
Division of Research Kaiser Permanente
mi
from
Oakland, CA
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Status: Enrolling
Updated: 12/31/1969
Division of Research Kaiser Permanente
mi
from
Oakland, CA
Click here to add this to my saved trials
A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined rTMS and BCI Training
A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined Repetitive Transcranial Magnetic Stimulation and Brain-Computer Interface Training
Status: Enrolling
Updated:  12/31/1969
Clinical and Translational Science Institute
mi
from
Minneapolis, MN
A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined rTMS and BCI Training
A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined Repetitive Transcranial Magnetic Stimulation and Brain-Computer Interface Training
Status: Enrolling
Updated: 12/31/1969
Clinical and Translational Science Institute
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12284
mi
from
Tuscaloosa, AL
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12284
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10358
mi
from
Anaheim, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10738
mi
from
Glendale, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10738
mi
from
Glendale, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 004
mi
from
Irvine, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 004
mi
from
Irvine, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 004
mi
from
Irvine, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 004
mi
from
Irvine, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 176
mi
from
Loma Linda, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 176
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 174
mi
from
Norwalk, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 174
mi
from
Norwalk, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10665
mi
from
Oceanside, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10665
mi
from
Oceanside, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10665
mi
from
Oceanside, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10665
mi
from
Oceanside, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10140
mi
from
Orange, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10140
mi
from
Orange, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
San Diego, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 169
mi
from
San Rafael, CA
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 169
mi
from
San Rafael, CA
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 038
mi
from
Englewood, CO
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 038
mi
from
Englewood, CO
Click here to add this to my saved trials
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12287
mi
from
Washington,
Reducing Involuntary Movements in Tardive Dyskinesia
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12287
mi
from
Washington,
Click here to add this to my saved trials